Sakar Healthcare Ltd
SAKARSakar Healthcare Ltd
SAKARPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
64.19 | 4.62 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 5.95 | 0.56% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sakar Healthcare ltd. is engaged in providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 35.06 | 41.44 | 44.90 | 53.61 | 68.93 | 85.00 | 95.92 | 130.40 | 138.03 | 155.18 | ||||||||||
Raw Materials | 18.24 | 21.88 | 22.82 | 27.38 | 35.57 | 42.90 | 52.20 | 73.69 | 74.00 | 115.77 | ||||||||||
Power & Fuel Cost | 3.27 | 3.23 | 2.43 | 2.43 | 3.23 | 3.31 | 2.26 | 3.01 | 2.90 | |||||||||||
Employee Cost | 3.80 | 4.49 | 5.64 | 6.55 | 8.45 | 11.61 | 12.74 | 14.26 | 15.81 | |||||||||||
Selling & Administrative Expenses | 1.38 | 2.15 | 3.05 | 2.56 | 3.23 | 4.49 | 4.36 | 5.60 | 6.60 | |||||||||||
Operating & Other expenses | 0.46 | 1.15 | 0.07 | 1.58 | 0.91 | 1.12 | 0.58 | 2.26 | 0.91 | |||||||||||
EBITDA | 7.91 | 8.54 | 10.89 | 13.11 | 17.54 | 21.57 | 23.78 | 31.58 | 37.81 | 39.41 | ||||||||||
Depreciation/Amortization | 2.50 | 2.73 | 3.39 | 4.41 | 6.04 | 7.08 | 8.06 | 9.67 | 14.99 | 16.73 | ||||||||||
PBIT | 5.41 | 5.81 | 7.50 | 8.70 | 11.50 | 14.49 | 15.72 | 21.91 | 22.82 | 22.68 | ||||||||||
Interest & Other Items | 2.99 | 2.94 | 2.69 | 2.59 | 2.27 | 2.26 | 2.48 | 2.90 | 5.95 | 7.67 | ||||||||||
PBT | 2.42 | 2.87 | 4.81 | 6.11 | 9.23 | 12.23 | 13.24 | 19.01 | 16.87 | 15.01 | ||||||||||
Taxes & Other Items | 0.58 | 0.64 | 1.44 | 2.30 | 2.54 | 2.60 | 2.55 | 3.76 | 4.12 | 2.53 | ||||||||||
Net Income | 1.84 | 2.23 | 3.37 | 3.81 | 6.69 | 9.63 | 10.69 | 15.25 | 12.75 | 12.48 | ||||||||||
EPS | 2.30 | 2.79 | 3.55 | 3.29 | 4.92 | 6.44 | 6.99 | 9.32 | 7.05 | 6.55 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sakar Healthcare Ltd | 62.83 | 4.62 | — |
Sun Pharmaceutical Industries Ltd | 45.89 | 6.56 | 0.71% |
Cipla Ltd | 43.13 | 5.10 | 0.57% |
Dr Reddy's Laboratories Ltd | 22.75 | 4.40 | 0.65% |
Price Comparison
Compare SAKAR with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 7.57%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SAKAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
News & Opinions
Sakar Healthcare consolidated net profit declines 21.14% in the September 2022 quarter
1 year ago•Business Standard
Sakar Healthcare standalone net profit declines 93.89% in the December 2021 quarter
2 years ago•Business Standard
Sakar Healthcare standalone net profit declines 46.05% in the September 2021 quarter
2 years ago•Business Standard
Sakar Healthcare’s fully-integrated anti-cancer formulation unit now starts with Research Lab; Stock ends 2% up
2 years ago•India Infoline
Sakar Healthcare standalone net profit rises 40.93% in the June 2021 quarter
2 years ago•Business Standard
Swiss-based HBM Healthcare invests Rs14.85cr in Sakar Healthcare through COBRA wing
2 years ago•India Infoline
BRIEF-Sakar Healthcare Says HBM Healthcare Investments Invested 148.5 Mln Rupees In Co
2 years ago•Investing.com
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 20.82%, vs industry avg of 8.36%
Increasing Market Share
Over the last 5 years, market share increased from 0.03% to 0.04%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 27.33%, vs industry avg of 9.82%